Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it-Reference-Cited by-同舟云学术

Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it

Published:2023-02-11 Issue:5 Volume:70 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Brock Penelope¹^ORCID,Meijer Annelot²,Kogner Per³,Ansari Marc⁴,Capra Michael⁵,Geller James⁶^ORCID,Heuvel‐Eibrink Marry van den²,Knight Kristin⁷,Kruger Mariana⁸^ORCID,Lindemulder Susan⁹,Maibach Rudolf¹⁰,O'Neill Allison¹¹^ORCID,Papadakis Vassilios¹²^ORCID,Rajput Kaukab¹³,Bleyer Archie¹⁴^ORCID,Bouffet Eric¹⁵^ORCID,Sullivan Michael¹⁶

Affiliation:

1. Department of Paediatric Oncology Great Ormond Street Hospital for Children NHS Foundation Trust London UK

2. Department of Pediatric Oncology Prinses Maxima Centrum Utrecht The Netherlands

3. Department of Pediatric Oncology and Childhood Cancer Research Unit Karolinska Institutet Stockholm Sweden

4. Pediatric Hematology and Oncology Geneva University Hospital Geneva Switzerland

5. Paediatric Oncology Our Lady's Children's Hospital Dublin Ireland

6. Division of Oncology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

7. Department of Pediatric Audiology Oregon Health and Science University Portland Oregon USA

8. Department of Paediatrics and Child Health Stellenbosch University Stellenbosch South Africa

9. Department of Pediatric Oncology Oregon Health and Science University Portland Oregon USA

10. Department of Statistics International Breast Cancer Study Group Bern Switzerland

11. Children's Cancer and Blood Disorders Center Dana Farber Cancer Institute Boston Massachusetts USA

12. Department of Pediatric Oncology Agia Sofia Children's Hospital Athens Greece

13. Department of Paediatric Audiology Great Ormond Street Hospital for Children NHS Foundation Trust London UK

14. Radiation Oncology, Knight Cancer Institute Oregon Health and Science University Portland Oregon USA

15. Division of Pediatric Neuro‐Oncology The Hospital for Sick Children Toronto Ontario Canada

16. Children's Cancer Centre and Department of Paediatric Oncology Royal Children's Hospital Melbourne Victoria Australia

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30248

Reference20 articles.

1. Early Changes in Auditory Function As a Result of Platinum Chemotherapy: Use of Extended High-Frequency Audiometry and Evoked Distortion Product Otoacoustic Emissions

2. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study

3. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma

4. The cumulative incidence of cisplatin‐induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments

5. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment;Ear & Hearing;2024-09-12

2. Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature;Journal of Clinical Oncology;2024-06-20

3. Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss;Pharmaceuticals;2024-06-05

4. FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing Loss;2024-05-21

5. Oseltamivir (Tamiflu), a Commonly Prescribed Antiviral Drug, Mitigates Hearing Loss in Mice;2024-05-08